Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Retained Earnings (2017 - 2025)

Arcus Biosciences has reported Retained Earnings over the past 9 years, most recently at -$1.5 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.5 billion for Q4 2025, down 31.18% from a year ago — trailing twelve months through Dec 2025 was -$1.5 billion (down 31.18% YoY), and the annual figure for FY2025 was -$1.5 billion, down 31.18%.
  • Retained Earnings for Q4 2025 was -$1.5 billion at Arcus Biosciences, down from -$1.4 billion in the prior quarter.
  • Over the last five years, Retained Earnings for RCUS hit a ceiling of -$2000.0 in Q1 2021 and a floor of -$1.5 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$374.9 million (2021), compared with a mean of -$508.2 million.
  • Biggest five-year swings in Retained Earnings: soared 100.0% in 2021 and later tumbled 516093.48% in 2022.
  • Arcus Biosciences' Retained Earnings stood at -$275.0 million in 2021, then plummeted by 97.09% to -$542.0 million in 2022, then plummeted by 56.64% to -$849.0 million in 2023, then tumbled by 33.33% to -$1.1 billion in 2024, then crashed by 31.18% to -$1.5 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.5 billion (Q4 2025), -$1.4 billion (Q3 2025), and -$1.2 billion (Q2 2025) per Business Quant data.